Prostate cancer screening: The home urine test that could help detect the disease

PROSTATE cancer is the most common cancer in men in the UK, but like all cancers there ’s currently no cure. Early detection can help ensure a better chance of survival and make treatment more successful, and a new test could revolutionise diagnosis.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

Authors: Bratu OG, Diaconu CC, Mischianu DLD, Constantin T, Stanescu AMA, Bungau SG, Ionita-Radu F, Marcu RD Abstract Prostate cancer is the second most common form of cancer in men in Europe. The primary treatment of this type of cancer is radical prostatectomy, which has shown good oncological results. Radical prostatectomy (open, laparoscopic or robotic) has high success and low morbidity rates in patients with localized prostate cancer. The life expectancy is>10 years after radical prostatectomy. Studies have shown that ~20%-30% of the patients who have undergone radical prostatectomy can develop biochemical...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Guo Q, Lv S, Wang B, Li Y, Cha N, Zhao R, Bao W, Jia B Abstract Long non-coding RNAs (lncRNAs) have important roles in the development and progression of various types of human cancer. However, the expression and function of the lncRNA prostate cancer-associated non-coding RNA 1 (PRNCR1) in breast cancer remains unclear. Reverse transcription-quantitative PCR was performed to measure the levels of mRNA expression. Cell counting kit-8, flow cytometry, wound healing and Transwell assays were also performed to study cell proliferation, cell cycle, migration and invasion, respectively. The results of the prese...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
CONCLUSIONS: In all the instances, statistical analysis showed that mean mSWAT score before/after SN diagnosis had a significantly difference (p value=0.0037) suggesting that patients with a SN may have a worse clinical outcome. By secreting immunosuppressive cytokines or recruiting immunosuppressive cells, a sort of mutual help between the two neoplasms may be prompted. Our data suggest that SN development in MF patients may be regarded as a worse prognostic marker. PMID: 31804054 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
Pembrolizumab shows limited activity in selected men with treatment-refractory metastatic castration-resistant prostate cancer (mCRPC), according to findings from the open-label KEYNOTE-199 study.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
CONCLUSION: Primary Signet ring cell carcinoma of the prostate is a rare and aggressive histological variant of adenocarcinomas of the prostate. Treatment is the same as classical adenocarcinoma with an emphasis on aggressive multimodal treatment. PMID: 31797810 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Authors: Yalcin S, Kaya E, Ebiloglu T, Akay S, Zor M, Sarıkaya S, Yilmaz S, Bedir S Abstract OBJECTIVES: In this research, we designed a cognitive fusion(CF) prostate biopsy(PB) (CFPB) technique by examining the multiparametric MRI of prostate (MP_MRI-P) images in a smart-phone near the trans-rectal ultrasound (TRUS) device, and examined the results. METHODS: Between January 2011 and January 2017, a total of 344 men who had PB enrolled in this study. Group 1 had a minimum of a 12-core standard TRUS PB (TRUSPB). Group 2 had CFPB while examining the MP_ MRI-P images in a smartphone near the TRUS device. A minimu...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Authors: Murray NP, Aedo S, Fuentealba C, Salazar A, Reyes E, Lopez MA, Minzer S Abstract INTRODUCTION: Minimal residual disease (MRD) is that which persists after curative treatment for prostate cancer. It has the potential to grow and cause metastasis. The detection of circulating prostate cells (CPCs) and bone marrow micro-metastasis could represent different sub-types of MRD. OBJECTIVE: To determine biochemical failure free survival and time to failure, the presence of circulating prostate cells and bone marrow micro-metastasis in men treated for low risk prostate cancer. HYPOTHESIS: The presence of MRD...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Conclusions There was variable uptake of the PtDAs between the cases. Men who received the PtDA had positive outcomes. Several strategies were identified to increase or sustain PtDA use. Implications for Practice Nurses have a key role in supporting men making decisions about prostate cancer treatment by providing PtDAs, answering questions, and advocating for men's preferences.
Source: Cancer Nursing - Category: Nursing Tags: ARTICLES: ONLINE ONLY Source Type: research
A breakthrough coming out of Duke University has the potential to treat prostate cancer cells that have become impervious to hormone therapy – presenting a wealth of potential therapeutic benefits as researchers press forward.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
CONCLUSION: Our preliminary analysis demonstrates that the high tumor burden represents the most important pre-treatment factor that could affect treatment completion and that needs to be considered before starting 223Ra-therapy to achieve a better outcome in mCRPC patients. PMID: 31802056 [PubMed - in process]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
More News: Cancer | Cancer & Oncology | Health | Prostate Cancer